Sign in
Taking peopleNo phase

Biomarkers and Imaging Markers for ICH

Key facts

Who runs it
Southwest Hospital, China
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
200 people, planned
Started
1 Jan 2014
Expected to end
1 Dec 2026
Type of study
Observational, 2 groups
Treatments tested
  • body sample collection and imaging scan
Record updated
17 June 2024

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Individuals aged 18-80 years
  • Hematoma size is more than 5 ml
  • Evidence of a spontaneous ICH on CT scan
  • Patient within 72 hours of ictus
  • Glasgow Coma Scale (GCS) Score of 5-15
  • The history of hypertension

Who cannot take part

  • If the haematological effects of any previous anticoagulants are not completely reversed
  • Clear evidence that the hemorrhage is due to an aneurysm, arteriovenous malformation or other cerebrovascular diseases
  • Patients with heart insufficiency, lungs insufficiency, renal insufficiency, hepatic insufficiency, autoimmune diseases and other organ diseases with severe dysfunction
  • Individuals with age < 18 years or > 80 years
  • ICH secondary to tumor or trauma

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Intracerebral hemorrhage (ICH) is a subtype of stroke associated with high mortality and disability. Basic and clinical research has contributed to our understanding of the complex pathophysiology in ICH. However, questions regarding acute diagnosis, therapeutic decisions, and prognostication of ICH remain unanswered. Molecular biomarkers and imaging markers have revolutionalized diagnosis and treatment of many diseases, such as troponin use in myocardial infarction and magnetic resonance imaging (MRI) scan in ischemic stroke. Therefore, the investigators aim to discovery the potential biomarkers by screening samples of blood, cerebral spinal fluid, urine, saliva, and even tissues (if available) from ICH patients, and imaging markers via serial multimodality imaging scans such as computed tomography(CT), magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), positron emission tomography (PET), etc. These molecular and imaging markers would assist in contributing additional information to current tools for onset warning, diagnosis, therapy monitoring, risk stratification, intervention and prognosis for ICH patients.

The 2 groups in the trial

  • ICH group

    Patients with CT-demonstrated Intracerebral Hemorrhage (ICH) within 72 hours after symptom onset admitted to Southwest hospital.

    Treatment: body sample collection and imaging scan

  • Control group

    Age- and sex-matched healthy individuals were recruited from volunteers.

    Treatment: body sample collection and imaging scan

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Biomarkers and Imaging Markers Screening for Intracerebral Hemorrhage Patients
Criteria questions
Built from NCT06462274, who can take part
Record updated
17 June 2024